Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin glargine/lixisenatide - Sanofi

Drug Profile

Insulin glargine/lixisenatide - Sanofi

Alternative Names: AVE0010/Lantus®; HOE901/AVE0010; iGlarLixi; Insulin glargine/lixisenatide; Lantus®/lixisenatide single combination product; Lantus®/Lyxumia®; LixiLan; Lixisenatide + Lantus®; Lixisenatide/Lantus®; Lyxumia®/Lantus®; Soliqua; Soliqua®100/33; Suliqua

Latest Information Update: 15 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis; Zealand Pharma
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jan 2019 Phase-III clinical trials in Type 2 diabetes mellitus (Adjunctive treatment, New delivery system) in China (SC) (NCT03798054)
  • 16 Jan 2019 Sanofi plans a phase III trial for Type 2 diabetes mellitus (New delivery system) (NCT03798080)
  • 15 Jan 2019 Sanofi plans the phase III Lixilan-O-AP trial for Type 2 diabetes mellitus (Adjunctive treatment, New delivery system) (SC) (NCT03798054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top